(1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane | 293751-16-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane
• 英文别名: 2-amino-9-[(1S,3R,4R,7S)-1-(hydroxymethyl)-7-phenylmethoxy-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-1H-purin-6-one
• CAS: 293751-16-3
• 化学式: C₁₈H₁₉N₅O₅
• 分子量: 385.379
• InChiKey: UTPVXQZALPSCOB-RGFKIIKPSA-N

物化性质

• 沸点：
  710.9±70.0 °C(Predicted)
• 密度：
  1.74±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane 在 palladium 10% on activated carbon 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 0.25h， 生成 (1S,3R,4R,7S)-3-(guanin-9-yl)-7-hydroxy-1-hydroxymethyl-2,5-dioxabicyclo-[2.2.1]heptane
  参考文献：
  名称：

  IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES

  摘要：

  公开号：

  EP1163250B1
• 作为产物：
  描述：

  (1R,3R,4R,7S)-7-benzyloxy-1-methanesulfonyloxymethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane 在 sodium hydroxide 、 水 作用下， 反应 12.0h， 生成 (1S,3R,4R,7S)-7-benzyloxy-1-hydroxymethyl-3-(guanin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane
  参考文献：
  名称：

  IMPROVED SYNTHESIS OF ¬2.2.1|BICYCLO NUCLEOSIDES

  摘要：

  公开号：

  EP1163250B1

文献信息

• Synthesis of [2.2.1]bicyclo nucleosides
  申请人：Exiqon A/S

  公开号：US20030092905A1

  公开（公告）日：2003-05-15

  A synthesis of [2.2.1]bicyclo nucleosides which is shorter and provides higher overall yields proceeds via the key intermediate of the general formula III, wherein R 4 and R 5 are, for instance, sulfonates and R 7 is, for instance, a halogen or an acetate. From compounds of the general formula II, such as 3-O-aryl-4-C-hydroxymethyl-1,2-O-isopropylidene-&agr;-D-ribofuranose, intermediates of the general formula III are suitable for coupling with silylated nucleobases. Upon one-pot base-induced ring-closure and desulfonation of the formed [2.2.1]bicyclo nucleoside, a short route to each the LNA (Locked Nucleic Acid) derivatives of adenosine, cytosine, uridine, thymidine and guanidine is demonstrated. The use of the 5′-sulfonated ring-closed intermediate also allows for synthesis of 5′-amino- and thio-LNAs. 1

  通过通式III的关键中间体进行合成[2.2.1]双环核苷，该方法较短且提供更高的总收率，其中R4和R5例如为磺酸盐，R7例如为卤素或醋酸盐。从通式II的化合物，例如3-O-芳基-4-C-羟甲基-1,2-O-异丙基亚-D-核糖，通式III的中间体适用于与硅化核苷碱进行偶联。通过一锅法碱催化环闭合和去磺酸化形成的[2.2.1]双环核苷，演示了腺嘌呤、胞嘧啶、尿嘧啶、胸腺嘧啶和鸟嘌呤的LNA（锁定核酸）衍生物的短路线。使用5'-磺酸化环闭合中间体还允许合成5'-氨基和硫代-LNA。
• D-AMINO ACID COMPOUNDS FOR LIVER DISEASE
  申请人：Idenix Pharmaceuticals LLC

  公开号：US20160002281A1

  公开（公告）日：2016-01-07

  Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病和病状（包括HCV感染）的化合物、组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。
• [EN] D-AMINO ACID COMPOUNDS FOR LIVER DISEASE<br/>[FR] COMPOSÉS D'ACIDE D-AMINÉ CONTRE LES MALADIES HÉPATIQUES
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2013177219A1

  公开（公告）日：2013-11-28

  Provided herein are compounds comprising a D-amino acid, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了包含D-氨基酸的化合物、用于治疗肝脏疾病和状况（包括HCV感染）的组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒剂联合使用。
• 2′,4′-bridged nucleosides for HCV infection
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US10723754B2

  公开（公告）日：2020-07-28

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′,4′-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2′,4′-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.

  本文提供了用于治疗黄病毒科感染（包括 HCV 感染）的化合物、组合物和方法。在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独使用或与其他抗病毒药物联合使用。在某些实施方案中，这些化合物是2′,4′桥接核苷，在治疗人类HCV感染等方面具有显著的疗效和生物利用度。在某些实施方案中，2′，4′桥核苷为式3001： 或其药学上可接受的盐、溶液、立体异构体、同分异构体或多晶型，其中 PD、B、W、X、RA、RB、RC 和 RD 如本文所述。
• D-amino acid compounds for liver disease
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：US10717758B2

  公开（公告）日：2020-07-21

  Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝病和肝脏状况（包括 HCV 感染）的化合物、组合物和方法。在某些实施方案中，公开了核苷衍生物的化合物和组合物，可单独使用或与其他抗病毒药物联合使用。